Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
| ▸ | SGMS1 | Q86VZ5 | 11/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11358325 | 0.92 | TBXA2R (0.85) | TBXA2RTBXAS1SGMS1HTTALDH1A1 | |
| SCHEMBL9127040 | 0.90 | TBXA2R (0.81) | TBXA2RTBXAS1SGMS1HTTALDH1A1 | |
| SCHEMBL11332922 | 0.90 | TBXA2R (0.81) | TBXA2RTBXAS1SGMS1HTTALDH1A1 | |
| Sulotroban SCHEMBL11456215 | 0.89 | TBXA2R (0.79) | TBXA2RTBXAS1SGMS1HTTALDH1A1 | |
| SCHEMBL11348800 | 0.88 | TBXA2R (0.79) | TBXA2RTBXAS1SGMS1HTTALDH1A1 | |
| SCHEMBL11342321 | 0.88 | TBXA2R (0.79) | TBXA2RTBXAS1SGMS1HTTALDH1A1 | |
| SCHEMBL8840163 | 0.88 | TBXA2R (0.79) | TBXA2RTBXAS1SGMS1HTTALDH1A1 | |
| Sulotroban SCHEMBL9585833 | 0.88 | TBXA2R (0.79) | TBXA2RTBXAS1SGMS1HTTALDH1A1 | |
| SCHEMBL11371899 | 0.88 | TBXA2R (0.79) | TBXA2RTBXAS1SGMS1HTTALDH1A1 | |
| SCHEMBL9512082 | 0.87 | TBXA2R (0.76) | TBXA2RTBXAS1SGMS1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| US-20250144079-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2025-05-08 | — | — | US | claimed |
| US-20240041839-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| US-20230090578-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2023-03-23 | — | — | US | claimed |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| US-20200405694-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2020-12-31 | — | — | US | claimed |
| EP-3716973-A1 | METHODS OF INHIBITING TUMOR METASTASIS | Vanderbilt University (US) | 2020-10-07 | — | — | EP | claimed |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | ACORDA THERAPEUTICS, INC. | 2020-05-21 | — | — | US | claimed |
| WO-2016102352-A1 | TXA2 INHIBITOR AS STIMULATOR OR INDUCER OF MHC CLASS I CROSS-PRESENTATION | INSTITUT PASTEUR (FR) | 2016-06-30 | — | — | WO | claimed |
| EP-3037106-A1 | TXA2 inhibitor as stimulator or inducer of MHC Class I cross-presentation | INSTITUT PASTEUR (FR) | 2016-06-29 | — | — | EP | claimed |
| WO-1996017606-A1 | USE OF INFLAMMATORY MODULATORS IN THE TREATMENT OF CHRONIC OR RECALCITRANT SKIN DAMAGE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-06-13 | — | — | WO | claimed |
| US-5324749-A | Anticholesterol, antiischemic agents | BOEHRINGER MANNHEIM GMBH (DE) | 1994-06-28 | — | — | US | claimed |
| EP-0558062-A2 | Phenoxyacetic acid derivatives and pharmaceutical compositions containing them | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-09-01 | — | — | EP | claimed |
| EP-0523086-A1 | PHARMACEUTICAL AQUEOUS SOLUTION OF 4- 2-(BENZOLSULPHONYLAMINO)-ETHYL]-PHENOXYACETIC ACID | Roche Diagnostics GmbH (DE) | 1993-01-20 | — | — | EP | claimed |
| EP-0268581-B1 | PROSTACYCLINES, THEIR ANALOGUES OR PROSTAGLANDINES AND THROMBOXANE ANTAGONISTS FOR THE TREATMENT OF THROMBOTIC AND THROMBO-EMBOLIC ILLNESSES | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-04-08 | — | — | EP | claimed |
| WO-1991015202-A1 | PHARMACEUTICAL AQUEOUS SOLUTION OF 4-[2-(BENZOLSULPHONYLAMINO)-ETHYL]-PHENOXYACETIC ACID | BOEHRINGER MANNHEIM GMBH (DE) | 1991-10-17 | — | — | WO | claimed |
| EP-0449764-A2 | A method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor and/or thromboxane receptor antagonist | CIBA-GEIGY AG (CH) | 1991-10-02 | — | — | EP | claimed |
| US-5021448-A | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist | CIBA-GEIGY CORPORATION (US) | 1991-06-04 | — | — | US | claimed |
| EP-0300675-A2 | Method for the improvement of cyclosporine therapy | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | claimed |
| US-4258058-A | Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation inhibition | BOEHRINGER MANNHEIM GMBH (DE) | 1981-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144079-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | TBXA2R 1/4885TBXAS1 4/4885SGMS1 3147/4885 |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | TBXA2R 1641/4885TBXAS1 1697/4885SGMS1 969/4885 |
| US-20240041839-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | TBXA2R 1/4885TBXAS1 4/4885SGMS1 3147/4885 |
| US-20200405694-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | TBXA2R 1/4885TBXAS1 4/4885SGMS1 3147/4885 |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | TBXA2R 1641/4885TBXAS1 1697/4885SGMS1 969/4885 |
| US-20230090578-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | TBXA2R 1/4885TBXAS1 4/4885SGMS1 3147/4885 |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | EPB41L2, MYLK2, RABL3 | TBXA2R 2982/4885TBXAS1 220/4885SGMS1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.